Dexmedetomidine decreases cerebral blood flow velocity in humans

Mark Zornow, Mervyn Maze, J. Barry Dyck, Steven L. Shafer

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

This study was designed to determine the effects of dexmedetomidine on CBF velocity as measured by transcranial Doppler sonography in human volunteers. Dexmedetomidine, a potent a-2 adrenergic agonist, was administered by computer-driven infusion pump to six male volunteers. Serial measurements of middle cerebral artery blood flow velocity at four steady-state plasma concentrations of dexmedetomidine were made with a 2-MHz transcranial Doppler transducer via the temporal window. The targeted plasma concentrations were 0.49, 0.65, 0.81, and 0.97 ng/ml. These represent 60, 80, 100, and 120%, respectively, of the mean peak concentration following the intramuscular administration of 2 μg/kg of dexmedetomidine. Subjects experienced a significant degree of sedation at the highest infusion rates. Mean CBF velocity decreased with each increase in plasma concentration of dexmedetomidine and then began to return to basal levels after termination of the infusion. A trend toward an increase in the pulsatility index at the higher levels of dexmedetomidine suggests that the observed decrement in CBF velocity was due to an increase in cerebral vascular resistance. Upon initiation of the drug infusion, mean arterial pressure decreased from ∼95 mm Hg to 78 mm Hg. There were no further decreases in arterial pressure with subsequent increases in plasma concentrations of dexmedetomidine. Arterial carbon dioxide tension increased to a maximum of 45 mm Hg during the drug infusion, but this increase from baseline was not statistically significant. These studies are in agreement with previous animal studies which demonstrate a decrease in CBF after administration of dexmedetomidine.

Original languageEnglish (US)
Pages (from-to)350-353
Number of pages4
JournalJournal of Cerebral Blood Flow and Metabolism
Volume13
Issue number2
StatePublished - 1993
Externally publishedYes

Fingerprint

Cerebrovascular Circulation
Dexmedetomidine
Blood Flow Velocity
Volunteers
Arterial Pressure
Doppler Transcranial Ultrasonography
Infusion Pumps
Adrenergic Agonists
Middle Cerebral Artery
Transducers
Carbon Dioxide
Pharmaceutical Preparations
Vascular Resistance

Keywords

  • α
  • 2 adrenergic agonist
  • Cerebral blood flow
  • Dexmedetomidine
  • Human
  • Sympathetic nervous system
  • Transcranial Doppler

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Neuroscience(all)

Cite this

Dexmedetomidine decreases cerebral blood flow velocity in humans. / Zornow, Mark; Maze, Mervyn; Barry Dyck, J.; Shafer, Steven L.

In: Journal of Cerebral Blood Flow and Metabolism, Vol. 13, No. 2, 1993, p. 350-353.

Research output: Contribution to journalArticle

Zornow, Mark ; Maze, Mervyn ; Barry Dyck, J. ; Shafer, Steven L. / Dexmedetomidine decreases cerebral blood flow velocity in humans. In: Journal of Cerebral Blood Flow and Metabolism. 1993 ; Vol. 13, No. 2. pp. 350-353.
@article{f3bfb1b72b424b1f9fbea1c12146ed5e,
title = "Dexmedetomidine decreases cerebral blood flow velocity in humans",
abstract = "This study was designed to determine the effects of dexmedetomidine on CBF velocity as measured by transcranial Doppler sonography in human volunteers. Dexmedetomidine, a potent a-2 adrenergic agonist, was administered by computer-driven infusion pump to six male volunteers. Serial measurements of middle cerebral artery blood flow velocity at four steady-state plasma concentrations of dexmedetomidine were made with a 2-MHz transcranial Doppler transducer via the temporal window. The targeted plasma concentrations were 0.49, 0.65, 0.81, and 0.97 ng/ml. These represent 60, 80, 100, and 120{\%}, respectively, of the mean peak concentration following the intramuscular administration of 2 μg/kg of dexmedetomidine. Subjects experienced a significant degree of sedation at the highest infusion rates. Mean CBF velocity decreased with each increase in plasma concentration of dexmedetomidine and then began to return to basal levels after termination of the infusion. A trend toward an increase in the pulsatility index at the higher levels of dexmedetomidine suggests that the observed decrement in CBF velocity was due to an increase in cerebral vascular resistance. Upon initiation of the drug infusion, mean arterial pressure decreased from ∼95 mm Hg to 78 mm Hg. There were no further decreases in arterial pressure with subsequent increases in plasma concentrations of dexmedetomidine. Arterial carbon dioxide tension increased to a maximum of 45 mm Hg during the drug infusion, but this increase from baseline was not statistically significant. These studies are in agreement with previous animal studies which demonstrate a decrease in CBF after administration of dexmedetomidine.",
keywords = "α, 2 adrenergic agonist, Cerebral blood flow, Dexmedetomidine, Human, Sympathetic nervous system, Transcranial Doppler",
author = "Mark Zornow and Mervyn Maze and {Barry Dyck}, J. and Shafer, {Steven L.}",
year = "1993",
language = "English (US)",
volume = "13",
pages = "350--353",
journal = "Journal of Cerebral Blood Flow and Metabolism",
issn = "0271-678X",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Dexmedetomidine decreases cerebral blood flow velocity in humans

AU - Zornow, Mark

AU - Maze, Mervyn

AU - Barry Dyck, J.

AU - Shafer, Steven L.

PY - 1993

Y1 - 1993

N2 - This study was designed to determine the effects of dexmedetomidine on CBF velocity as measured by transcranial Doppler sonography in human volunteers. Dexmedetomidine, a potent a-2 adrenergic agonist, was administered by computer-driven infusion pump to six male volunteers. Serial measurements of middle cerebral artery blood flow velocity at four steady-state plasma concentrations of dexmedetomidine were made with a 2-MHz transcranial Doppler transducer via the temporal window. The targeted plasma concentrations were 0.49, 0.65, 0.81, and 0.97 ng/ml. These represent 60, 80, 100, and 120%, respectively, of the mean peak concentration following the intramuscular administration of 2 μg/kg of dexmedetomidine. Subjects experienced a significant degree of sedation at the highest infusion rates. Mean CBF velocity decreased with each increase in plasma concentration of dexmedetomidine and then began to return to basal levels after termination of the infusion. A trend toward an increase in the pulsatility index at the higher levels of dexmedetomidine suggests that the observed decrement in CBF velocity was due to an increase in cerebral vascular resistance. Upon initiation of the drug infusion, mean arterial pressure decreased from ∼95 mm Hg to 78 mm Hg. There were no further decreases in arterial pressure with subsequent increases in plasma concentrations of dexmedetomidine. Arterial carbon dioxide tension increased to a maximum of 45 mm Hg during the drug infusion, but this increase from baseline was not statistically significant. These studies are in agreement with previous animal studies which demonstrate a decrease in CBF after administration of dexmedetomidine.

AB - This study was designed to determine the effects of dexmedetomidine on CBF velocity as measured by transcranial Doppler sonography in human volunteers. Dexmedetomidine, a potent a-2 adrenergic agonist, was administered by computer-driven infusion pump to six male volunteers. Serial measurements of middle cerebral artery blood flow velocity at four steady-state plasma concentrations of dexmedetomidine were made with a 2-MHz transcranial Doppler transducer via the temporal window. The targeted plasma concentrations were 0.49, 0.65, 0.81, and 0.97 ng/ml. These represent 60, 80, 100, and 120%, respectively, of the mean peak concentration following the intramuscular administration of 2 μg/kg of dexmedetomidine. Subjects experienced a significant degree of sedation at the highest infusion rates. Mean CBF velocity decreased with each increase in plasma concentration of dexmedetomidine and then began to return to basal levels after termination of the infusion. A trend toward an increase in the pulsatility index at the higher levels of dexmedetomidine suggests that the observed decrement in CBF velocity was due to an increase in cerebral vascular resistance. Upon initiation of the drug infusion, mean arterial pressure decreased from ∼95 mm Hg to 78 mm Hg. There were no further decreases in arterial pressure with subsequent increases in plasma concentrations of dexmedetomidine. Arterial carbon dioxide tension increased to a maximum of 45 mm Hg during the drug infusion, but this increase from baseline was not statistically significant. These studies are in agreement with previous animal studies which demonstrate a decrease in CBF after administration of dexmedetomidine.

KW - α

KW - 2 adrenergic agonist

KW - Cerebral blood flow

KW - Dexmedetomidine

KW - Human

KW - Sympathetic nervous system

KW - Transcranial Doppler

UR - http://www.scopus.com/inward/record.url?scp=0027510650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027510650&partnerID=8YFLogxK

M3 - Article

C2 - 8094720

AN - SCOPUS:0027510650

VL - 13

SP - 350

EP - 353

JO - Journal of Cerebral Blood Flow and Metabolism

JF - Journal of Cerebral Blood Flow and Metabolism

SN - 0271-678X

IS - 2

ER -